Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Non-Randomized Trial of Bruxism-Related TMD Treatments

NCT: NCT07586072 · COMPLETED

NCT IDNCT07586072
StatusCOMPLETED
Start Date2024-08-05
Completion2025-08-01

Brief Summary

This study compares three treatment approaches for adults with bruxism-related temporomandibular disorder symptoms: occlusal splint therapy, botulinum toxin type A injection, and combined medical-splint therapy. Participants were assigned to one of three non-randomized treatment arms according to clinical indication, symptom profile, shared decision-making, and patient preference. Symptom severity was assessed before treatment and after 3 months using the Fonseca Anamnestic Index. The primary purpose of the study was to compare the 3-month change in total Fonseca Anamnestic Index scores among the treatment arms. Selected symptom items and treatment-related adverse events were also evaluated during follow-up.

Frequently Asked Questions

What is Non-Randomized Trial of Bruxism-Related TMD Treatments?

Non-Randomized Trial of Bruxism-Related TMD Treatments is a clinical trial registered under NCT07586072. Current status: COMPLETED.

What is the status of NCT07586072?

The current status of NCT07586072 (Non-Randomized Trial of Bruxism-Related TMD Treatments) is: COMPLETED.

When did Non-Randomized Trial of Bruxism-Related TMD Treatments start?

Non-Randomized Trial of Bruxism-Related TMD Treatments started on 2024-08-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.